Aptevo Therapeutics (APVO)
(Delayed Data from NSDQ)
$0.41 USD
-0.01 (-1.56%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $0.40 -0.01 (-2.22%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth C Momentum B VGM
Brokerage Reports
Aptevo Therapeutics Inc. [APVO]
Reports for Purchase
Showing records 61 - 80 ( 96 total )
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Will Advance Bispecific ALG.APV-527 Into Phase 1 Given Solid APVO436 Data
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
3Q20: APVO436 Showing Potential, Cash Into 1H22
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
APVO436 Drives a Second CR in AML in Cohort 6, Adopts Rights Plan
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
APVO436 Delivers First Complete Remission in Cohort 6 of a Phase 1 Trial
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
APVO436 Progresses Safely into Dose Cohort Seven Without Eliciting ADAs
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
2Q20: APVO436 - Preclinical Pipeline Progressing Well Despite COVID-19
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Ruxience Royalty Could Be Meaningful Revenue Over Next Seven Years
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Preclinical Results Support ALG.APV-527 as a Promising Therapy
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
1Q20: IXINITY Sale Complete, Debt Free, APVO436 Trial Enrolling Cohort Six
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Approaching APVO436 Doses Likely to Show Clinical Utility - Reports 4Q19
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
We are transferring coverage to Jonathan Aschoff, Ph.D., with a Buy rating and a $3 target price
Provider: Roth Capital Partners, Inc.
Analyst: Research Department